Case number 1:22-cv-01045
Novartis Pharmaceuticals Corporation v. Ingenus Pharmaceuticals, LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 31, 2023 | 38 | Report to the Commissioner of Patents and Trademarks. (ntl) (Entered: 07/31/2023) (4) |
| Jul 28, 2023 | 37 | STIPULATION of Dismissal by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 07/28/2023) (2) |
| Jun 20, 2023 | 36 | NOTICE requesting Clerk to remove Angela X. Gao as co-counsel.. (Joyce, Alexandra) (Entered: 06/20/2023) (1) |
| Jun 7, 2023 | 35 | NOTICE OF SERVICE of (1) Plaintiff's Objections and Responses to Defendant's Second Set of Requests for Production (Nos. 16-95) and (2) Plaintiff's Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-10) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (2) |
| Apr 18, 2023 | 34 | SO ORDERED, re 31 STIPULATION and [Proposed] Order Regarding Claim Construction and to Amend the Case Scheduling Order filed by Novartis Pharmaceuticals Corporation. The Markman Hearing scheduled for 9/27/23 is CANCELLED. Signed by Judge Gregory B. Williams on 4/18/23. (ntl) (Entered: 04/18/2023) (3) |
| Apr 17, 2023 | 33 | NOTICE OF SERVICE of (1) Defendant Ingenus Pharmaceuticals, LLC's First Set of Interrogatories to Plaintiff (Nos. 1-10) and (2) Defendant Ingenus Pharmaceuticals, LLC's Second Set of Requests for Production of Documents and Things (Nos. 16-95) filed by Ingenus Pharmaceuticals, LLC.(Metzler, Sara) (Entered: 04/17/2023) (2) |
| Apr 10, 2023 | 32 | NOTICE OF SERVICE of Plaintiff's Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 04/10/2023) (2) |
| Apr 3, 2023 | 31 | STIPULATION and [Proposed] Order Regarding Claim Construction and to Amend the Case Scheduling Order by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 04/03/2023) (3) |
| Mar 31, 2023 | 30 | NOTICE OF SERVICE of Defendant Ingenus Pharmaceuticals, LLC's Notice of Claim Terms for Construction filed by Ingenus Pharmaceuticals, LLC.(Metzler, Sara) (Entered: 03/31/2023) (1) |
| Mar 31, 2023 | 29 | NOTICE OF SERVICE of Plaintiff's Notice Identifying No Claim Terms for Construction filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/31/2023) (2) |
| Mar 16, 2023 | 28 | NOTICE OF SERVICE of (1) Defendant Ingenus Pharmaceuticals, LLC's Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-4); (2) Defendant's Objections and Responses to Plaintiff's First Set of Requests for Production (Nos. 1-59); and (3) Defendant Ingenus Pharmaceuticals, LLC's Initial Invalidity Contentions filed by Ingenus Pharmaceuticals, LLC.(Metzler, Sara) (Entered: 03/16/2023) (2) |
| Mar 8, 2023 | 27 | NOTICE OF SERVICE of Defendant Ingenus Pharmaceuticals, LLC's Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery, Including Discovery of Electronically Store Information filed by Ingenus Pharmaceuticals, LLC.(Metzler, Sara) (Entered: 03/08/2023) (2) |
| Feb 13, 2023 | 26 | NOTICE OF SERVICE of (1) Plaintiff's First Set of Interrogatories to Defendant Ingenus Pharmaceuticals, LLC (Nos. 1-4), (2) Plaintiff's First Set of Requests for Production to Defendant Ingenus Pharmaceuticals, LLC (Nos. 1-58), and (3) Plaintiff's Initial Claim Charts to Defendant Ingenus Pharmaceuticals, LLC filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 02/13/2023) (2) |
| Feb 8, 2023 | 25 | NOTICE OF SERVICE of Defendant Ingenus Pharmaceuticals, LLC's Rule 26(a)(1) Initial Disclosures filed by Ingenus Pharmaceuticals, LLC.(Metzler, Sara) (Entered: 02/08/2023) (1) |
| Feb 8, 2023 | 24 | NOTICE OF SERVICE of Plaintiff Novartis Pharmaceuticals Corporation's Fed. R. Civ. P. 26(a) Initial Disclosures filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/08/2023) (2) |
| Feb 3, 2023 | 23 | SCHEDULING ORDER: Fact Discovery completed by 2/9/2024. Status Report due by 11/15/2023. Joint Claim Construction Brief due by 7/21/2023. A Markman Hearing is set for 9/27/2023 at 10:00 AM in Courtroom 6B before Judge Gregory B. Williams. A Final Pretrial Conference is set for 10/10/2024 at 10:00 AM in Courtroom 6B before Judge Gregory B. Williams. A 5-day Bench Trial is set for 10/21/2024 at 09:30 AM in Courtroom 6B before Judge Gregory B. Williams. Signed by Judge Gregory B. Williams on 2/3/2023. (etg) (Entered: 02/03/2023) (15) |
| Jan 30, 2023 | 22 | PROPOSED ORDER Stipulated Protective Order by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 01/30/2023) (30) |
| Jan 19, 2023 | 21 | NOTICE OF SERVICE of Defendant Ingenus Pharmaceuticals LLC's Core Technical Documents pursuant to paragraph 4(b) of Delaware's Default Standard for Discovery filed by Ingenus Pharmaceuticals, LLC.(Metzler, Sara) (Entered: 01/19/2023) (2) |
| Dec 29, 2022 | 20 | NOTICE OF SERVICE of Plaintiff's Objections and Responses to Defendant's First Set of Requests for Production (Nos. 1-15) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 12/29/2022) (2) |
| Dec 15, 2022 | 19 | NOTICE OF SERVICE of Plaintiff's Disclosure of Accused Products and Asserted Patents Pursuant to Paragraph 4(a) of Delaware's Default Standard for Discovery filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (2) |
| Dec 9, 2022 | 18 | PROPOSED ORDER Scheduling Order re 17 Order,,,, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/09/2022) (16) |
| Dec 2, 2022 | 17 | ORAL ORDER: Having reviewed the parties' Joint Proposed Scheduling Order, D.I. 15, and having observed that the parties request at least seven (7) changes to the Court's form scheduling order (available at https://www.ded.uscourts.gov/judge/judge-gregory-b-williams under Forms, Patent (ANDA)) in at least paragraphs 3(a), 3(c), 3(e)(i), 3(e)(ii), 3(f)(i), 3(f)(ii), and 3(g)(v), IT IS HEREBY ORDERED that, no later than December 9, 2022, the parties shall submit an amended joint Proposed Scheduling Order adding the following language in a footnote to Paragraph 3: "The parties understand and expressly agree that the Court will not be responsible to hear and/or resolve any discovery disputes arising from or related to the alteration of the terms of Judge Williams' form scheduling order for patent, ANDA cases. With respect to those specific alterations, the parties will be left to resolve any such discovery disputes between themselves." The Markman hearing will be held on August 29, 2023 at 2:00 p.m. The pre-trial conference will be held on October 10, 2024 at 10:00 a.m., and the bench trial will begin at 9:30 a.m. on October 21, 2024. ORDERED by Judge Gregory B. Williams on 12/2/22. (ntl) (Entered: 12/02/2022) (0) |
| Nov 29, 2022 | 16 | NOTICE OF SERVICE of Defendant Ingenus Pharmaceuticals LLCs First Set of Requests for Production of Documents and Things filed by Ingenus Pharmaceuticals, LLC.(Farnan, Kelly) (Entered: 11/29/2022) (1) |
| Nov 22, 2022 | 15 | Letter to The Honorable Gregory B. Williams from Alexandra M. Joyce, Esq. regarding Proposed Scheduling Order. (Attachments: # 1 Proposed Scheduling Order)(Joyce, Alexandra) (Entered: 11/22/2022) (Proposed Scheduling Order) (15) |
| Nov 22, 2022 | 15 | Letter to The Honorable Gregory B. Williams from Alexandra M. Joyce, Esq. regarding Proposed Scheduling Order. (Attachments: # 1 Proposed Scheduling Order)(Joyce, Alexandra) (Entered: 11/22/2022) (Main Document) (1) |
| Nov 8, 2022 | 14 | MOTION for Pro Hac Vice Appearance of Attorney Bruce R. Genderson, Jessamyn S. Berniker, Christopher J. Mandernach, Kevin D. Hoagland-Hanson, Kathryn E. Garza, and Angela X. Gao - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Bruce R. Genderson, Jessamyn S. Berniker, Christopher J. Mandernach, Kevin D. Hoagland-Hanson, Kathryn E. Garza, and Angela X. Gao)(Joyce, Alexandra) (Entered: 11/08/2022) (Certifications for Bruce R. Genderson, Jessamyn S. Berniker, Christopher J. Man) (6) |
| Nov 8, 2022 | 14 | MOTION for Pro Hac Vice Appearance of Attorney Bruce R. Genderson, Jessamyn S. Berniker, Christopher J. Mandernach, Kevin D. Hoagland-Hanson, Kathryn E. Garza, and Angela X. Gao - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Bruce R. Genderson, Jessamyn S. Berniker, Christopher J. Mandernach, Kevin D. Hoagland-Hanson, Kathryn E. Garza, and Angela X. Gao)(Joyce, Alexandra) (Entered: 11/08/2022) (Main Document) (2) |
| Nov 2, 2022 | 13 | MOTION for Pro Hac Vice Appearance of Attorney Steven E. Feldman, Sherry L. Rollo and Anandita Vyakarnam - filed by Ingenus Pharmaceuticals, LLC. (Farnan, Kelly) (Entered: 11/02/2022) (4) |
| Oct 28, 2022 | 12 | ORAL ORDER: IT IS HEREBY ORDERED that, not later than thirty (30) days from the date of this Order, the parties shall meet and confer and file a joint proposed Scheduling Order in this action consistent with the applicable form Scheduling Order of Judge Williams, which is posted at http://www/ded/uscourts.gov (See Chambers, Judge Williams, Forms), along with a cover letter requesting the Court to enter the joint proposed Scheduling Order (if there are no disputes or other issues concerning scheduling that the Court needs to address) or to schedule the Scheduling Conference. If there are disputes or other issues the Court needs to address in the joint proposed Scheduling Order, in the cover letter, the parties shall direct the Court to the paragraph numbers in the joint proposed Scheduling Order which those appear. ORDERED by Judge Gregory B. Williams on 10/28/22. (ntl) (Entered: 10/28/2022) (0) |
| Oct 28, 2022 | 11 | NOTICE of Appearance by Sara M. Metzler on behalf of Ingenus Pharmaceuticals, LLC (Metzler, Sara) (Entered: 10/28/2022) (1) |
| Oct 11, 2022 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Ingenus Holdings, LLC for Ingenus Pharmaceuticals, LLC filed by Ingenus Pharmaceuticals, LLC. (Farnan, Kelly) (Entered: 10/11/2022) (1) |
| Oct 11, 2022 | 9 | ANSWER to 1 Complaint, by Ingenus Pharmaceuticals, LLC.(Farnan, Kelly) (Entered: 10/11/2022) (30) |
| Sep 16, 2022 | 8 | NOTICE of Appearance by Kelly E. Farnan on behalf of Ingenus Pharmaceuticals, LLC (Farnan, Kelly) (Entered: 09/16/2022) (1) |
| Aug 18, 2022 | 7 | WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Ingenus Pharmaceuticals, LLC waiver sent on 8/11/2022, answer due 10/11/2022. (Silver, Daniel) (Entered: 08/18/2022) (1) |
| Aug 10, 2022 | 6 | Summons Issued as to Ingenus Pharmaceuticals, LLC on 8/10/2022. (lam) (Entered: 08/10/2022) (2) |
| Aug 9, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attachment. (Attachments: # 1 Patent/Trademark Report 2)(lam) (Entered: 08/10/2022) (Patent/Trademark Report 2) (1) |
| Aug 9, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (lam) (Main Document 5 replaced on 8/10/2022) (lam). (Entered: 08/10/2022) (2) |
| Aug 9, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attachment. (Attachments: # 1 Patent/Trademark Report 2)(lam) (Entered: 08/10/2022) (Main Document) (1) |
| Aug 9, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/15/2020, 7/6/2022. Date of Expiration of Patent: (See Attachment)Thirty Month Stay Deadline: 1/11/2024. (lam) (Entered: 08/10/2022) (2) |
| Aug 9, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lam) (Entered: 08/10/2022) (3) |
| Aug 9, 2022 | 1 | Complaint* (1) |
